One Case of a BRCA1 Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding.

Korean Journal of Pathology Pub Date : 2014-10-01 Epub Date: 2014-10-27 DOI:10.4132/KoreanJPathol.2014.48.5.379

Hyun Joo Kim, Jung Min Park, Hyoun Wook Lee, Eun Hee Lee, Min Kyu Kim

{"title":"One Case of a BRCA1 Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding.","authors":"Hyun Joo Kim, Jung Min Park, Hyoun Wook Lee, Eun Hee Lee, Min Kyu Kim","doi":"10.4132/KoreanJPathol.2014.48.5.379","DOIUrl":null,"url":null,"abstract":"Ovarian cancer is one of the most lethal gynecological cancers in the Western world. In 2012, approximately 2,000 new patients and 980 mortalities due to ovarian cancer were reported in Korea. Due to the lack of efficient diagnostic methods for early detection and rapid progression to advanced stages, patients with ovarian cancer have poor survival rates. As hereditary ovarian cancers tend to present as higher grade disease in younger patients, screening for hereditary ovarian cancer is important for decreasing prevalence and improving patient survival. BRCA1 and BRCA2 are mismatch repair genes accounting for 85% of hereditary breast and epithelial ovarian cancers. 1 They are located on chromosomes 17q21 (22 exons, 80-kb DNA) and 13q12-13 (26 exons, 70-kb DNA), 2,3 respectively. Other mismatch repair genes also contribute to carcinogenesis. 4 The average lifetime risk of developing breast and ovarian cancers in women with a BRCA1 mutation are 65% and 39%, respectively, and the corresponding estimates for BRCA2 are 45% and 11%, respectively. 5 Three methods are commonly used to man","PeriodicalId":49936,"journal":{"name":"Korean Journal of Pathology","volume":"48 5","pages":"379-81"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4132/KoreanJPathol.2014.48.5.379","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4132/KoreanJPathol.2014.48.5.379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/10/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer is one of the most lethal gynecological cancers in the Western world. In 2012, approximately 2,000 new patients and 980 mortalities due to ovarian cancer were reported in Korea. Due to the lack of efficient diagnostic methods for early detection and rapid progression to advanced stages, patients with ovarian cancer have poor survival rates. As hereditary ovarian cancers tend to present as higher grade disease in younger patients, screening for hereditary ovarian cancer is important for decreasing prevalence and improving patient survival. BRCA1 and BRCA2 are mismatch repair genes accounting for 85% of hereditary breast and epithelial ovarian cancers. 1 They are located on chromosomes 17q21 (22 exons, 80-kb DNA) and 13q12-13 (26 exons, 70-kb DNA), 2,3 respectively. Other mismatch repair genes also contribute to carcinogenesis. 4 The average lifetime risk of developing breast and ovarian cancers in women with a BRCA1 mutation are 65% and 39%, respectively, and the corresponding estimates for BRCA2 are 45% and 11%, respectively. 5 Three methods are commonly used to man

Abstract Image